Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors

Fig. 4

PK profiles of ITC-6102RO. (A) In rats, the pharmacokinetic profiles of tAb (total antibody) and acDrug (antibody-conjugated drug) after intravenous administration of 3 mg/kg ITC-6102RO. (B) The drug-antibody ratio (DAR) profiles in rat plasma for ITC-6102RO. The number of conjugated linker drugs per antibody was quantified using HIC-HPLC analysis

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us